Edition:
India

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.59CAD
20 Aug 2018
Change (% chg)

$-0.04 (-6.35%)
Prev Close
$0.63
Open
$0.62
Day's High
$0.62
Day's Low
$0.59
Volume
954,201
Avg. Vol
1,310,908
52-wk High
$1.80
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

Prometic Life Sciences Incurred Net Loss Of $34.6 Mln For Quarter
Wednesday, 16 May 2018 

May 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS 2018 FIRST QUARTER HIGHLIGHTS AND FINANCIAL RESULTS.PROMETIC LIFE SCIENCES INC - TOTAL REVENUES FOR Q1 ENDED MARCH 31, 2018 WERE $4.3 MILLION COMPARED TO $4.9 MILLION FOR Q1 ENDED MARCH 31, 2017.PROMETIC LIFE SCIENCES INC - CORP INCURRED NET LOSS OF $34.6 MILLION FOR QUARTER VERSUS A NET LOSS OF $29.1 MILLION.  Full Article

Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial
Monday, 30 Apr 2018 

April 30 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL.PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS.PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS.  Full Article

Prometic reports positive interim clinical data from IVIG phase 3 trial
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​.  Full Article

Prometic Q3 revenue C$24 million versus C$3.7 million
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Prometic Life Sciences Inc :Prometic reports 2017 third quarter highlights and financial results.Q3 revenue C$24 million versus C$3.7 million.Q3 revenue view c$6.9 million -- Thomson Reuters I/B/E/S.Prometic Life Sciences - ‍incurred a net loss of $17.8 million for quarter ended sept 30, compared to net loss of $28.0 million for quarter ended Sept 30, 2016​.  Full Article

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Prometic Life Sciences Inc ::Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation.Prometic Life Sciences Inc - ‍up to 33 adult patients are expected to be enrolled in clinical trial​.  Full Article

Prometic enters LOI for $80 mln line of credit from Structured Alpha LP
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Prometic Life Sciences Inc ::Prometic enters into binding letter of intent to secure usd $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.Company to grant Structured Alpha LP an initial 10 million warrants with an exercise price of CAD $1.70 per common share​.Company to also grant Structured Alpha LP additional 44 million warrants at exercise price of CAD $1.70 per common share​.  Full Article

FDA accepts Prometic's Biologics License Application for Plasminogen
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Prometic Life Sciences Inc :Prometic announces FDA acceptance of its Biologics License Application for Plasminogen (Ryplazim™).Prometic Life Sciences Inc - ‍prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018​.  Full Article

Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome
Wednesday, 12 Oct 2016 

Prometic Life Sciences Inc : Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome . Prometic Life Sciences-significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment . Prometic Life Sciences Inc - liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment . Prometic Life Sciences Inc - alström syndrome clinical program to be expanded to include further sites throughout europe and north america .Prometic Life Sciences-drug safety monitoring board recommended patient enrolment should continue in co's ongoing alström syndrome phase 2 clinical trial.  Full Article

Telesta says ISS, Glass Lewis recommend shareholders vote for plan of arrangement between co, Prometic Life Sciences
Tuesday, 11 Oct 2016 

Telesta Therapeutics Inc :Leading independent advisory firms ISS and Glass Lewis recommend shareholders vote for the plan of arrangement Between Telesta Therapeutics Inc and Prometic Life Sciences Inc.  Full Article

ProMetic announces the addition of tympanic membrane perforations to its plasminogen's targeted indications
Tuesday, 6 Sep 2016 

ProMetic Life Sciences Inc : Will be pursuing tympanic membrane perforations as one of its new plasma-derived plasminogen targeted clinical indications . Expects to file its clinical trial application in Q4 2016 .Expects to initiate clinical trial in Sweden in patients suffering from chronic tympanic membrane perforations in H1 2017.  Full Article